Biochemical and pharmacological aspects of the thrombin inhibitor hirudin
Walsmann, P.; Markwardt, F.
Die Pharmazie 36(10): 653-660
1981
ISSN/ISBN: 0031-7144 PMID: 7031705 Document Number: 171081
Document emailed within 1 workday
Related Documents
Rubens, F.D.; Ross-Ouellet, B.; Dennie, C.; Coates, G.; Kinlough-Rathbone, R.L.; Hatton, M.W. 1994: Displacement of fibrin-bound thrombin by r-hirudin precludes the use of 131I-r-hirudin for detecting pulmonary emboli in the rabbit Thrombosis and Haemostasis 72(2): 232-238Rübsamen, K.; Hornberger, W.; Kirchengast, M. 1995: Inhibition of arterial thrombus formation in two canine models: comparison of ancrod, a fibrinogen-depleting agent, the thrombin-inhibitor r-hirudin, and the glycoprotein 11b/IIIa-receptor antagonist Ro 43-8857 Thrombosis and Haemostasis 74(5): 1353-1360
Kudriashov, B.A.; Baskova, I.P.; Orlova, A.S.; Shapiro, F.B. 1981: Effect of hirudin-thrombin and phenylmethylsulfonyl-thrombin on various blood clotting indices Biulleten' Eksperimental'noi Biologii i Meditsiny 91(3): 307-309
Kaiser, B.; Hauptmann, J.; Weiss, A.; Markwardt, F. 1985: Pharmacological characterization of a new highly effective synthetic thrombin inhibitor Biomedica Biochimica Acta 44(7-8): 1201-1210
Jackson, C.V.; Crowe, V.G.; Frank, J.D.; Wilson, H.C.; Coffman, W.J.; Utterback, B.G.; Jakubowski, J.A.; Smith, G.F. 1992: Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis Journal of Pharmacology and Experimental Therapeutics 261(2): 546-552
Reid, T.J.; Alving, B.M. 1993: A quantitative thrombin time for determining levels of hirudin and Hirulog Thrombosis and Haemostasis 70(4): 608-616
Rowand, J.K.; Marucha, P.; Berliner, L.J. 1992: Hirudin C-terminal fragments inhibit thrombin induced neutrophil chemotaxis Thrombosis and Haemostasis 67(3): 289-291
Scuvée-Moreau, J.; Dresse, A. 1982: Monoamines and endogenous depression. Biochemical and pharmacological aspects Revue Medicale de Liege 37(1): 1-7
Klöcking, H.P.; Hoffmann, A.; Markwardt, F. 1988: Influence of hirudin on the thrombin-induced release of tissue plasminogen activator from isolated perfused pig ear Folia Haematologica 115(1-2): 110-112
Rangoonwala, B.; Rosenthal, I. 1998: Management of hypertension and its sequelae with ACE inhibitors: biochemical, pharmacological and clinical aspects International Journal of Clinical Practice 52(7): 492-500
Bouclier, M.; Hensby, C.N. 1986: Biochemical, pharmacological and therapeutic aspects of skin metabolism of arachidonic acid Annales de Dermatologie et de Venereologie 113(12): 1289-1293
Horn, A.S. 1977: Chemical, pharmacological and biochemical aspects of clomipramine. the binding of inhibitors of serotonin uptake to biological receptors Postgraduate Medical Journal 53(Suppl 4): 9-13
Markwardt, F.; Hauptmann, J.; Nowak, G.; Klessen, C.; Walsmann, P. 1982: Pharmacological studies on the antithrombotic action of hirudin in experimental animals Thrombosis and Haemostasis 47(3): 226-229
Caputo, R.P.; Giambartolomei, A.; Simons, A.; Reger, M.; Wagner, S.; Esente, P. 2001: Adjunctive therapies in the cath lab. use of combination glycoprotein IIb/IIIa inhibitor and direct thrombin inhibitor drugs to support percutaneous coronary stent placement in a patient with renal insufficiency and heparin-induced thrombocytopenia Journal of Invasive Cardiology 13(9): 657-660
Momi, S.; Nasimi, M.; Colucci, M.; Nenci, G.G.; Gresele, P. 2001: Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition Haematologica 86(3): 297-302
Knabb, R.M.; Kettner, C.A.; Timmermans, P.B.; Reilly, T.M. 1992: In vivo characterization of a new synthetic thrombin inhibitor Thrombosis and Haemostasis 67(1): 56-59
Binnie, C.G.; Lord, S.T. 1991: A synthetic analog of fibrinogen alpha 27-50 is an inhibitor of thrombin Thrombosis and Haemostasis 65(2): 165-168
Rossi, E.B.; Duboscq, C.L.; Kordich, L.C. 1999: Heparin cofactor II, a thrombin inhibitor with a still not clarified physiologic role Medicina 59(1): 95-104
Hara, H.; Tamao, Y.; Kikumoto, R.; Funahara, Y.; Hijikata, A.; Okamoto, S. 1980: Effect of a potent thrombin inhibitor, No. 407, on platelet function in vitro and in vivo Kobe Journal of Medical Sciences 26(1): 47-60
Tapparelli, C.; Metternich, R.; Gfeller, P.; Gafner, B.; Powling, M. 1995: Antithrombotic activity in vivo of SDZ 217-766, a low-molecular weight thrombin inhibitor in comparison to heparin Thrombosis and Haemostasis 73(4): 641-647